Thermo Fisher Scientific has unveiled the TacroType Pharmacogenetic Test, a new laboratory developed test designed to help inform clinicians on dosing tacrolimus, a commonly prescribed immunosuppressive drug for transplant recipients to lower the risk of rejection.
The new test provides clinicians with actionable genetic insights that can support more personalized tacrolimus dosing decisions. Using a simple buccal swab sample, the test identifies a patient’s CYP3A5 genotype, which influences how quickly tacrolimus is metabolized and how a patient may respond to therapy.
When performed prior to transplant, TacroType provides genetic information that may help inform early tacrolimus dosing decisions. This insight enables more informed initial dosing decisions that complement, rather than replace, ongoing therapeutic drug monitoring. By moving beyond conventional dosing approaches, clinicians may be able to reduce the risk of adverse effects while supporting better long-term graft and patient outcomes.
The TacroType test is offered as a one-time pharmacogenetic assessment using rapid, qPCR-based CYP3A5 genotyping services. By providing clinicians with patient-specific information to support tacrolimus dosing decisions, the test may enable clinicians to help patients reach target tacrolimus levels more efficiently and with fewer dose adjustments.
To learn more about TacroType, visit https://www.thermofisher.com/tacrotype.
The TacroType Pharmacogenetic Test is a laboratory developed test that is used for clinical purposes by the CLIA-certified laboratory performing the test. The test has not been cleared or approved by the U.S. Food and Drug Administration (FDA) or CE marked in the EU as an in vitro diagnostic test.
